Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: A novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect

Bioconjugate Chemistry

Volumn 13, Issue 2, 2002, Pages 206-215

  Kovář, Marek ^a   Strohalm, Jiří ^b   Etrych, Tomáš ^b   Ulbrich, Karel ^b   Říhová, Blanka ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHAINS; CONTROLLED DRUG DELIVERY; CYTOLOGY; DRUG PRODUCTS; TARGETED DRUG DELIVERY;

ANTI-TUMORS; ANTIBODY-TARGETED; ANTITUMOR EFFECT; CYTOSTATIC ACTIVITIES; DOXORUBICIN; DOXORUBICIN CONJUGATES; IN-VITRO; METHACRYLAMIDES; NON-TARGETED; STARS:STRUCTURE;

MONOCLONAL ANTIBODIES;

ANIMALIA;

ANTINEOPLASTIC AGENT; DOXORUBICIN; HYDROXYPROPYL METHACRYLATE; IMMUNOTOXIN; METHACRYLIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; POLYMER;

ANIMAL; ARTICLE; B CELL LEUKEMIA; BAGG ALBINO MOUSE; CELL CULTURE; CELL DIVISION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; IC 50; IMMUNOLOGY; KINETICS; LEUKOCYTE; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELLS, CULTURED; DOXORUBICIN; DRUG DELIVERY SYSTEMS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; KINETICS; LEUKEMIA, B-CELL; LEUKOCYTES; METHACRYLATES; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; POLYMERS;

EID: 0036009640     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc010063m     Document Type: Article

References (35)

1. Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug)
2. Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used
3. 125DNM
4. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates
5. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs
6. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens
7. Antibody-targeted polymer-bound drugs
8. Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: Visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies
9. Lectin-mediated drug targeting: Quantification of binding and internalization of Wheat germ agglutinin and Solanum tuberosum lectin using Caco-2 and HT-29 cells
10. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma
11. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide conjugates in A/J and B10 mice
12. Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids
13. Therapeutic effect of treatment with polyclonal or monoclonal antibodies to alpha-fetoprotein that have been conjugated to daunomycin via a dextran bridge: Studies with an alpha-fetoprotein-producing rat hepatoma tumor model
14. Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model
15. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies
16. In vivo study of mIgM and mIgD cross-linking on murine B cells
17. Cytoplasmic tail deletion converts membrane immunoglobulin to a phosphatidylinositol-linked form lacking signaling and efficient antigen internalization functions
18. Antiproliferative effect of a lectin- and anti-thy-1.2 antibody targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse thy-1.2 gene
19. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physicochemical characterisation
20. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide) copolymers by bovine spleen cathepsin B
21. Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide
22. Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumor activity measured in vivo
23. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies
24. Biological properties of targetable poly N-(2-hydroxypropyl)methacrylamide-antibody conjugates
25. Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers
26. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier
27. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: Potential drug carriers
28. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes
29. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro
30. Immunotoxin therapy of leptomeningeal neoplasia
31. Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using anti-idiotypic antibodies coupled to the A chain of ricin
32. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice
33. Immunotoxin sensitivity of Chinese hamster ovary cells expressing human transferrin receptors with differing internalization rates
34. Use of "star-like" macromolecular prodrugs in cancer therapy
35. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab′)(2)-targeted conjugates and combined therapy with immunomodulators